Sana Biotechnology stockholders elect three Class II directors; ratify EY as auditor

Sana Biotechnology, Inc.

Hans E. Bishop elected with 117,452,573 For vs 57,148,432 Withheld; 30,606,441 broker non-votes.
Robert Nelsen elected with 160,384,193 For vs 14,216,812 Withheld; 30,606,441 broker non-votes.
Alise S. Reicin, M.D. elected with 149,865,546 For vs 24,735,459 Withheld; 30,606,441 broker non-votes.
Ratification of Ernst & Young LLP as independent auditor for FY2026: 203,932,500 For, 831,419 Against, 443,527 Abstain.
All director terms expire at 2029 annual meeting; no changes to board composition.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Sana Biotechnology, Inc. shareholders approved Election of Class II directors for a three-year term expiring at the 2029 annual meeting at the 2026-06-04 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

Proposal 1: The Company’s stockholders elected all the nominees to serve as Class II directors of the Company’s Board of Directors, each to serve for a three-year term expiring at the Company’s 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified, by the votes set forth in the table below:

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Sana Biotechnology, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-04 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

Proposal 2: The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, by the votes set forth in the table below:

View on SEC.gov

1656 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Sana Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-259532

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.